Items where authors include "Maraveyas, A."

Article

Collinson, F. orcid.org/0000-0001-6964-6406, Royle, K.-L. orcid.org/0000-0003-0225-1199, Swain, J. orcid.org/0000-0003-2729-3029 et al. (28 more authors) (2024) Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health Technology Assessment, 28 (45). ISSN 1366-5278

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G., Brown, S. et al. (24 more authors) (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. ISSN 0732-183X

Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G. orcid.org/0000-0002-9952-8440, Brown, S. orcid.org/0000-0002-7975-7537 et al. (24 more authors) (2023) Standard versus modified ipilimumab, in combination with nivolumab, in advanced renal cell carcinoma: a randomized phase II trial (PRISM). Journal of Clinical Oncology. JCO2300236. ISSN 0732-183X

Brown, M., O’Connor, D., Turkington, R. et al. (8 more authors) (2023) Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series. BMC Sports Science, Medicine and Rehabilitation, 15 (1). 116. ISSN 2052-1847

Brown, J.E. orcid.org/0000-0003-4960-3032, Royle, K.-L., Gregory, W. et al. (96 more authors) (2023) Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. The Lancet Oncology, 24 (3). pp. 213-227. ISSN 1470-2045

Corrie, P.G., Marshall, A., Nathan, P.D. et al. (36 more authors) (2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8). pp. 1843-1852.

Ahmad, S.S., Qian, W., Ellis, S. et al. (26 more authors) (2015) Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients. Melanoma Research, 25 (5). pp. 432-442. ISSN 0960-8931